Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 6/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.53 |
| ▸ | KYNU | Q16719 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14842312 | 1.00 | SYK (0.64) | SYKPPARACTSSMAPTCTSK | |
| SCHEMBL14496968 | 0.95 | SYK (0.71) | SYKPPARACTSSCTSKCTSL | |
| SCHEMBL479093 | 0.95 | SYK (0.71) | SYKPPARACTSSCTSKCTSL | |
| SCHEMBL479092 | 0.95 | SYK (0.71) | SYKPPARACTSSCTSKCTSL | |
| SCHEMBL20297671 | 0.93 | SYK (0.64) | SYKPPARACTSSMAPTCTSK | |
| SCHEMBL18340847 | 0.93 | SYK (0.64) | SYKPPARACTSSMAPTCTSK | |
| SCHEMBL17841824 | 0.91 | SYK (0.65) | SYKPPARACTSSMAPTCTSK | |
| SCHEMBL1022494 | 0.91 | SYK (0.65) | SYKPPARACTSSMAPTCTSK | |
| SCHEMBL606625 | 0.91 | SYK (0.65) | SYKPPARACTSSMAPTCTSK | |
| SCHEMBL1626508 | 0.90 | SYK (0.67) | SYKPPARACTSSMAPTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | PARDES BIOSCIENCES INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4387980-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023023631-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11065343-B2 | Compound bearing beta-galactoside-introduced self-immolative linker | INTOCELL INC. (KR) | 2021-07-20 | — | — | US | disclosed |
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MERCK SHARP & DOHME CORP. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3654968-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp & Dohme Corp. (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20190328902-A1 | Compound Bearing Beta-Galactoside-Introduced Self-Immolative Linker | INTOCELL INC. (KR) | 2019-10-31 | — | — | US | disclosed |
| WO-2019018186-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-2763976-B1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9216173-B2 | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140243336-A1 | 2-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | MERCK SHARP & DOHME LLC | 2014-08-28 | — | — | US | disclosed |
| EP-2763976-A1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013052394-A1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-1259532-B1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING SPA (IT) | 2005-05-04 | — | — | EP | disclosed |
| US-6803030-B2 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | BRACCO IMAGING S.P.A. (IT) | 2004-10-12 | — | — | US | disclosed |
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | BRACCO IMAGING S.P.A. (IT) | 2003-06-19 | — | — | US | disclosed |
| EP-1259532-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | Bracco Imaging S.p.A. (IT) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001064708-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING S.P.A. (IT) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MLX, MMP12, SLC11A2 | SYK 839/4885PPARA 3476/4885CTSS 308/4885 |
| US-11065343-B2 | Compound bearing beta-galactoside-introduced self-immolative linker | DDOST, B3GAT3, GALNT10 | SYK 874/4885PPARA 4737/4885CTSS 2542/4885 |
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CPN1, CTSL | SYK 2724/4885PPARA 4532/4885CTSS 12/4885 |
| US-20190328902-A1 | Compound Bearing Beta-Galactoside-Introduced Self-Immolative Linker | DDOST, B3GAT3, GALNT10 | SYK 874/4885PPARA 4737/4885CTSS 2542/4885 |
| US-20140243336-A1 | 2-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | SYK, BTK, LCK | SYK 1/4885PPARA 2582/4885CTSS 1328/4885 |
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | SLC10A2, SLC10A1, NR1H4 | SYK 3492/4885PPARA 3055/4885CTSS 2698/4885 |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MLX, MMP12, SLC11A2 | SYK 839/4885PPARA 3476/4885CTSS 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.